These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20160745)

  • 1. The (possible) impact of comparative effectiveness research on pharmaceutical industry decision making.
    Chalkidou K
    Clin Pharmacol Ther; 2010 Mar; 87(3):264-6. PubMed ID: 20160745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facts, fallacies, and politics of comparative effectiveness research: Part I. Basic considerations.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E23-54. PubMed ID: 20119474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
    Towse A
    Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation and decision making in the UK.
    Buxton MJ
    Pharmacoeconomics; 2006; 24(11):1133-42. PubMed ID: 17067197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facts, fallacies, and politics of comparative effectiveness research: Part 2 - implications for interventional pain management.
    Manchikanti L; Falco FJ; Boswell MV; Hirsch JA
    Pain Physician; 2010; 13(1):E55-79. PubMed ID: 20119475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE's Medical Technologies Evaluation Programme (MTEP).
    Chapman AM; Taylor CA; Girling AJ
    Appl Health Econ Health Policy; 2014 Aug; 12(4):347-57. PubMed ID: 24934924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The accountability problem of the National Institute for Health and Clinical Excellence.
    Hasman A
    Med Law; 2008 Mar; 27(1):83-93. PubMed ID: 18592883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness research: the experience of the National Institute for Health and Clinical Excellence.
    Sorenson C; Drummond M; Chalkidou K
    J Clin Oncol; 2012 Dec; 30(34):4267-74. PubMed ID: 23071224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effective public health guidance: asking questions from the decision-maker's viewpoint.
    Chalkidou K; Culyer A; Naidoo B; Littlejohns P
    Health Econ; 2008 Mar; 17(3):441-8. PubMed ID: 17764094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective.
    Hao Y; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):447-54. PubMed ID: 23977973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality, bias and service user experience in healthcare: 10 years of mental health guidelines at the UK National Collaborating Centre for Mental Health.
    Kendall T; Glover N; Taylor C; Pilling S
    Int Rev Psychiatry; 2011 Aug; 23(4):342-51. PubMed ID: 22026490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public funding of new cancer drugs: Is NICE getting nastier?
    Mason AR; Drummond MF
    Eur J Cancer; 2009 May; 45(7):1188-1192. PubMed ID: 19138512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process.
    Schlander M
    J Med Ethics; 2008 Jul; 34(7):534-9. PubMed ID: 18591289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for cost effectiveness thresholds in the NHS.
    Appleby J; Devlin N; Parkin D; Buxton M; Chalkidou K
    Health Policy; 2009 Aug; 91(3):239-45. PubMed ID: 19168255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Straight talk with... Mark Sculpher. Interview by Kate Ravilious.
    Sculpher M
    Nat Med; 2012 Sep; 18(9):1315. PubMed ID: 22961148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.